Telcagepant failure is a headache for Merck (and perhaps Pfizer) but a break for others
01 August 2011
Daniel Chancellor
Please Login to read the full article.
01 August 2011
Daniel Chancellor
dchancellor@datamonitor.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- Alder raises $38 million in Series D round to advance cancer, migraine and other programs
- Pozen migraine drug licensed to Desitin for commercialisation in Europe
- Stockwatch: The impossible takes a little too long
- Pozen sells Treximet royalties for $75M, bolstering partnering for PhIII CV drug
COMMENT
Other Informa Comment
EVENTS
Today
The Rembrandt Hotel, London
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
